logo
Microplastics found in human semen, follicular fluid

Microplastics found in human semen, follicular fluid

CNN2 days ago
Pollution
Water availability
Corporate newsFacebookTweetLink
Follow
Scientists have detected microplastics — the tiny and pervasive fragments now found in our seas, drinking water, food and, increasingly, living tissue — in human semen and follicular fluid, according to new research.
A small group of 25 women and 18 men participated in the research, published Tuesday in the journal Human Reproduction. Microplastics were detected in 69% of the follicular fluid samples and 55% of the seminal fluid samples. Follicular fluid is the liquid that surrounds an egg in an ovarian follicle.
The research is an abstract — a short summary of completed research — and has not yet been peer reviewed. It was presented Tuesday in Paris at the 41st Annual Meeting of the European Society of Human Reproduction and Embryology.
'Previous studies had already suggested this possibility, so the presence of microplastics in the human reproductive system is not entirely unexpected,' said lead research author Dr. Emilio Gómez-Sánchez, director of the assisted reproduction laboratory at Next Fertility Murcia in Spain, in a statement provided to the press. 'What did surprise us, however, is how widespread it is. This is not an isolated finding — it appears to be quite common.'
Microplastics are polymer fragments that range in size from less than 0.2 inches (5 millimeters) to 1/25,000th of an inch (1 micrometer). Polymers are chemical compounds with long chains of large and repetitive molecular units called monomers, and are known for being flexible and durable. Most plastics are synthetic polymers.
Plastics smaller than the measurement criteria for microplastics are considered nanoplastics, which are measured in billionths of a meter.
'Microplastics primarily enter the body through three routes: ingestion, inhalation, and skin contact,' Gómez-Sánchez said. 'From there, they can enter the bloodstream, which then distributes them throughout the body, including to the reproductive organs.'
In previous studies, the fragments have also been detected in various body parts or fluids including the lungs, placenta, brain, testicles, nose tissue at the base of the brain, penises and human stool.
'Decades of studies and the (US Food and Drug Administration) agree that microplastics are not a threat because exposure is extremely low and they are non-toxic,' said Dr. Chris DeArmitt, founder of the Plastics Research Council, via email.
However, while there is little to nothing known about the potential effects of microplastics on human health, chemicals used in plastic production — that often leach from plastics — are linked with health risks including hormonal disruptions, certain cancers, respiratory diseases and skin irritation.
The research participants were patients and donors at Next Fertility Murcia. The women were undergoing egg retrieval, formally known as follicular aspiration, for assisted reproduction, while the men were undergoing semen analysis. The authors stored and froze the samples in glass, then incubated them for two days before analyzing them using an imaging technique combining microscopy and infrared laser.
The research team also analyzed the containers used to collect and store samples to ensure they hadn't been contaminated with microplastics. The abstract doesn't disclose what materials the collection containers were made of.
Imaging revealed nine types of microplastics in the reproductive fluids. Over 50% of the follicular fluid samples contained polyamide (PA), polyurethane (PU) and polyethylene (PE), while polytetrafluoroethylene (PTFE) and polyethylene terephthalate (PET) were discovered in over 30% of the follicular fluid samples.
Polypropylene (PP), polyvinyl chloride (PVC) and polylactic acid (PLA) appeared in over 20% of the follicular fluid samples.
In the semen samples, 56% contained PTFE.
Synthetic polyamide is commonly known as nylon, often used in textiles, plastics and automotive parts. Polyurethane is commonly used in coatings, foams and adhesives for furniture, construction, automotive parts, footwear and more. Polyethylene and polypropylene are often found in packaging, construction uses and consumer goods, such as toys and kitchenware.
The plastic PTFE is widely used in nonstick cookware, while PET is found in many food and beverage containers. Polyvinyl chloride is often used in the construction, packaging and medical industries, while PLA is primarily found in food packing, medical implants and 3D-printed objects.
In most samples, the researchers found only one or two particles, but they detected up to five in others, Gómez-Sánchez said. Microplastic concentrations were higher in follicular fluid than in semen. However, the overall concentrations of microplastics in both fluids were relatively low when compared with the concentrations of non-plastic particles. The abstract didn't disclose what those non-plastic particles were.
'Sadly, (the findings) are not surprising,' said Dr. Matthew J. Campen — a researcher who helped lead the discoveries of microplastics in the brain and testicles — via email.
Though the research is preliminary, it does 'set the stage for more advanced studies of the relationship between plastics exposure and reproductive fitness,' added Campen, who wasn't involved in the study and is a regents' professor of pharmaceutical sciences at the University of New Mexico.
The research affirmed previous studies that had found microplastics in these reproductive fluids, and yet again raises important questions, including how these microplastics are absorbed in the intestine then transported to the gonads, Campen said.
'This suggests a very natural mechanism is being hijacked,' he added. 'It would also be important to assess plastics in the nanoscale range.'
People trying to conceive naturally or via in vitro fertilization may not need to be concerned about the findings, as they are only preliminary for now, Gómez-Sánchez said.
'We don't know if they have a direct effect on the capacity of a couple to conceive and carry a baby to term,' he added. 'Reproduction is a complex equation, and microplastics are a variable in this equation.'
The findings also can't yet be linked to more general health outcomes, experts said.
'So far, the effects of microplastics on humans have been mainly extrapolated from animal studies, where microplastics were administered at high concentrations,' Gómez-Sánchez said. 'We currently lack direct evidence regarding their impact on humans.'
Betsy Bowers, executive director of the EPS Industry Alliance, echoed these disclaimers and noted that the animal research results aren't indicative of harm at regular exposure levels. The EPS (expanded polystyrene) Industry Alliance is a North American trade association representing the EPS industry.
The finding that follicular fluid contained more microplastics than semen may be circumstantial, Gómez-Sánchez added, because the study group was small. However, when an ovary is stimulated for assisted reproduction, blood flow to the ovary increases, which may deliver more microplastics to the ovary, he explained.
Additional research is needed to identify the types and quantities of microplastics that could cause health problems, said Dr. Ranjith Ramasamy, a consultant urologist at Jumeirah American Clinic in Dubai. Ramasamy, who wasn't involved in the study, led the research that found microplastics in penises.
'The plan is to increase the number of cases and conduct a survey on lifestyle habits in order to determine if any of these habits are linked to higher concentrations of plastics found in the ovaries and seminal plasma,' Gómez-Sánchez said.
Gómez-Sánchez and the other researchers also plan to explore whether the presence of microplastics in reproductive fluids affects the quality of sperm and oocytes, he said. Oocytes are cells in ovaries that form an ovum, a mature female reproductive cell that can divide to create an embryo upon fertilization by sperm.
The significance of the findings isn't yet clear, but they should be considered an additional argument in favor of avoiding the use of plastics in our daily lives, said Dr. Carlos Calhaz-Jorge, professor of obstetrics and gynecology at the University of Lisbon in Portugal, in a news release. Calhaz-Jorge wasn't involved in the research.
Given the ubiquity of plastics, avoidance can be challenging, said Dr. Philip Landrigan, a pediatrician and director of the Program for Global Public Health and the Common Good at Boston College, via email. In addition to reducing obvious uses of plastic, you can also avoid using plastic cutting boards and eating ultraprocessed foods.
Also limit drinking water from plastic bottles, microwaving food in plastic containers and consuming hot food from plastic containers, Ramasamy said.
Food can be stored in glass, stainless steel or bamboo instead of plastic.
But 'the conversation needs to shift — immediately — to policymakers,' Campen said. 'Hoping that individual choices can make a difference has been clearly a losing strategy. Federal governments around the world need to make major changes to waste management and recycling policies.'
Annual plastic production by weight has increased by 250 times in the past 75 years and is on track to triple again by 2060, Landrigan said.
'To reduce plastic pollution and safeguard human health, it will be essential that the Global Plastics Treaty that is currently in negotiation at the United Nations impose a global cap on plastic production,' Landrigan, who wasn't involved in the research, added.
'But smart governments can act now,' Campen urged.
Sign up for CNN's Life, But Greener newsletter. Our limited newsletter series guides you on how to minimize your personal role in the climate crisis — and reduce your eco-anxiety.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

GeoVax Highlights Critical Role of Multi-Antigen COVID-19 Vaccines as Nimbus Variant Underscores Persistent and Evolving Public Health Threat
GeoVax Highlights Critical Role of Multi-Antigen COVID-19 Vaccines as Nimbus Variant Underscores Persistent and Evolving Public Health Threat

Associated Press

time28 minutes ago

  • Associated Press

GeoVax Highlights Critical Role of Multi-Antigen COVID-19 Vaccines as Nimbus Variant Underscores Persistent and Evolving Public Health Threat

With COVID-19 continuing to mutate and over 40 million immunocompromised Americans still at risk, GeoVax's GEO-CM04S1 vaccine offers potential broader, more durable protection through a unique multi-antigen approach ATLANTA, GA - July 3, 2025 ( NEWMEDIAWIRE ) - GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing multi-antigen vaccines and immunotherapies, today emphasized the urgent need for innovation in COVID-19 vaccination as the NB.1.8.1 variant - commonly known as 'Nimbus' - spreads rapidly across the globe. Nimbus, a highly transmissible Omicron subvariant classified by the World Health Organization as a 'Variant Under Monitoring,' is now dominant in multiple U.S. states and surging across Europe and Asia. Though not more severe, its rapid spread and potential for immune escape reflect an increasingly clear reality: COVID-19 is not going away, and it will continue to evolve. 'The emergence of the Nimbus variant is a stark reminder that we need 'smarter' vaccines, not just newer ones,' said David Dodd, Chairman and CEO of GeoVax. 'Our GEO-CM04S1 vaccine was designed for this purpose and is built to potentially provide broader and longer-lasting protection, especially for the immunocompromised patients most at risk.' GEO-CM04S1: Multi-Antigen Protection for the Immunocompromised Unlike mRNA vaccines that rely solely on the Spike protein, GEO-CM04S1 delivers both Spike (S) and Nucleocapsid (N) antigens, stimulating an immune response that includes not only an antibody response, but also robust T-cell activity. This is believed to be critical for cross-variant protection and extended durability, particularly in individuals with weakened immune systems. GEO-CM04S1 is currently being evaluated in two Phase 2 clinical trials, focused on populations at greatest risk from COVID-19 complications, including blood cancer patients scheduled to receive stem cell transplant therapy. In one of the ongoing Phase 2 trials, the mRNA control arm was discontinued due to poor immunogenicity with the remainder of the trial only including GEO-CM04S1 which surpassed the immunogenicity target, reinforcing the limitations of monovalent vaccines and the important value of a multi-antigen vaccine approach in such high-risk patient populations. 'There are more than 40 million immunocompromised individuals in the U.S. alone,' said Dodd. 'They are underserved by the current, FDA-approved vaccine options that deliver only an antibody response and require a better solution with both breadth and longevity of protection.' Public Vaccine Policy and Regulatory Changes Support Platform Diversification Recent guidance from the U.S. Food and Drug Administration (FDA) calls for diversified vaccine platforms and risk-based regulatory pathways. Additionally, the CDC's narrowed 2025–2026 booster recommendations - now focused on adults 65+ and immunocompromised individuals - closely mirror GeoVax's clinical strategy and target population. GEO-CM04S1 has been proposed under BARDA's Rapid Response Partnership Vehicle (RRPV) for surge manufacturing support and integration into long-term public health preparedness efforts. The proposal, 'Innovation in Clinical Manufacturing of MVA-Vectored COVID-19 Vaccines', was selected by the RRPV, pending funding availability. 'As public health moves toward more targeted, durable, and inclusive vaccination strategies, GEO-CM04S1 is positioned to deliver where first generation COVID-19 vaccines fall short,' Dodd added. In addition to targeting today's variants, GEO-CM04S1 is structurally designed to adapt to future mutations and serve as a platform for multi-pathogen preparedness. As part of GeoVax's broader MVA-based portfolio, the platform underpins vaccine candidates for Mpox, smallpox, and hemorrhagic fever viruses, offering scale and flexibility across infectious disease threats. About GeoVax GeoVax Labs, Inc. is a clinical-stage biotechnology company developing novel vaccines against infectious diseases and therapies for solid tumor cancers. The Company's lead clinical program is GEO-CM04S1, a next-generation COVID-19 vaccine currently in three Phase 2 clinical trials, being evaluated as (1) a primary vaccine for immunocompromised patients such as those suffering from hematologic cancers and other patient populations for whom the current authorized COVID-19 vaccines are insufficient, (2) a booster vaccine in patients with chronic lymphocytic leukemia (CLL) and (3) a more robust, durable COVID-19 booster among healthy patients who previously received the mRNA vaccines. In oncology the lead clinical program is evaluating a novel oncolytic solid tumor gene-directed therapy, Gedeptin(R), having recently completed a multicenter Phase 1/2 clinical trial for advanced head and neck cancers. GeoVax is also developing a vaccine targeting Mpox and smallpox and, based on recent regulatory guidance, anticipates progressing directly to a Phase 3 clinical evaluation, omitting Phase 1 and Phase 2 trials. GeoVax has a strong IP portfolio in support of its technologies and product candidates, holding worldwide rights for its technologies and products. For more information about the current status of our clinical trials and other updates, visit our website: Forward-Looking Statements This release contains forward-looking statements regarding GeoVax's business plans. The words 'believe,' 'look forward to,' 'may,' 'estimate,' 'continue,' 'anticipate,' 'intend,' 'should,' 'plan,' 'could,' 'target,' 'potential,' 'is likely,' 'will,' 'expect' and similar expressions, as they relate to us, are intended to identify forward-looking statements. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our financial condition, results of operations, business strategy and financial needs. Actual results may differ materially from those included in these statements due to a variety of factors, including whether: GeoVax is able to obtain acceptable results from ongoing or future clinical trials of its investigational products, GeoVax's immuno-oncology products and preventative vaccines can provoke the desired responses, and those products or vaccines can be used effectively, GeoVax's viral vector technology adequately amplifies immune responses to cancer antigens, GeoVax can develop and manufacture its immuno-oncology products and preventative vaccines with the desired characteristics in a timely manner, GeoVax's immuno-oncology products and preventative vaccines will be safe for human use, GeoVax's vaccines will effectively prevent targeted infections in humans, GeoVax's immuno-oncology products and preventative vaccines will receive regulatory approvals necessary to be licensed and marketed, GeoVax raises required capital to complete development, there is development of competitive products that may be more effective or easier to use than GeoVax's products, GeoVax will be able to enter into favorable manufacturing and distribution agreements, and other factors, over which GeoVax has no control. Further information on our risk factors is contained in our periodic reports on Form 10-Q and Form 10-K that we have filed and will file with the SEC. Any forward-looking statement made by us herein speaks only as of the date on which it is made. Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. We undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by law. Company Contact: [email protected] 678-384-7220 Investor Relations Contact: [email protected] 212-698-8696 Media Contact: Jessica Starman [email protected]

M.Stanley takes neutral stance on Genmab ahead of portfolio, execution updates
M.Stanley takes neutral stance on Genmab ahead of portfolio, execution updates

Yahoo

time2 hours ago

  • Yahoo

M.Stanley takes neutral stance on Genmab ahead of portfolio, execution updates

-- Morgan Stanley has begun coverage of Genmab (CSE:GMAB) (NASDAQ:GMAB) with an Equal-Weight rating and a price objective of $24, reduced slightly from the previous $25 target. The Wall Street bank sees limited near-term upside as the most impactful catalysts are expected in 2026. 'Given that particular catalysts poised to most likely re-rate GMAB stock are anticipated to occur in 2026, we assume coverage at EW rating and look toward incremental updates on development timelines and commercial execution over the remainder of 2025,' analyst Judah C. Frommer said. Genmab is navigating a transition away from heavy reliance on Darzalex royalties and focusing more on its proprietary pipeline, particularly Epkinly, Rina-S, and acasunlimab. Following Johnson & Johnson (NYSE:JNJ)'s decision not to opt into the HexaBody-CD38 program, Frommer says attention will shift to maximizing internal pipeline value. For Epkinly, a supplemental BLA has been submitted in 2L+ follicular lymphoma based on the EPCORE-FL-1 study. While top-line data showed the study met one of its co-primary endpoints, progression-free survival data are still pending and expected later this year. More significant Phase III readouts for Epkinly in earlier-line DLBCL are scheduled for 2026. 'In the near-term however, focus remains on current commercial execution strategy in the 3L+ settings for DLBCL and FL as we await key data updates,' Frommer added. Meanwhile, Rina-S is progressing across multiple indications. At American Society of Clinical Oncology (ASCO), data in endometrial cancer showed response rates of 50% and 47% in two dose cohorts. The company plans to initiate a pivotal Phase III trial in 2L+ endometrial cancer in the second half of 2025 and a separate trial in platinum-sensitive ovarian cancer before year-end. Acasunlimab also remains a focus. Morgan Stanley expects updated Phase II data in 2L+ NSCLC later this year. The Phase III trial, which uses overall survival as the primary endpoint, is anticipated to read out in 2027. In sum, though Morgan Stanley views Genmab's management execution and pipeline-building strategy as sound, it sees 2026 as a more realistic timeframe for material stock re-rating. In the meantime, 'we look toward updates on development timelines and commercial execution over the remainder of 2025,' the bank said. Related articles takes neutral stance on Genmab ahead of portfolio, execution updates MS initiates coverage on AI Biotechs, flags key pipeline catalysts Chip stock targets raised at Mizuho following recent rally Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Insulin Resistance Linked to Faster Cognitive Decline in AD
Insulin Resistance Linked to Faster Cognitive Decline in AD

Medscape

time2 hours ago

  • Medscape

Insulin Resistance Linked to Faster Cognitive Decline in AD

Insulin resistance, detected using a simple and readily available blood test, may flag cognitive decline in patients with early Alzheimer's disease (AD), preliminary results of a new study suggested. Using the triglyceride-glucose (TyG) index to measure insulin resistance, investigators found that cognitive decline was four times faster in individuals with mild cognitive impairment (MCI) due to AD who had the highest insulin resistance levels compared to those with lower levels. The findings underline the importance of risk stratification strategies and early interventions to change the trajectory of cognitive decline, lead author Bianca Gumina, MD, neurology resident, Neurology Unit, Department of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy, told Medscape Medical News. 'The results suggest that in MCI-AD, the brain seems to be more vulnerable to metabolic stress. By identifying and addressing modifiable risk factors like metabolic health, we can use the tools we already have to potentially slow the disease course,' Gumina said. The results were presented on June 23 at the Congress of the European Academy of Neurology (EAN) 2025 in Helsinki, Finland. A 'Practical Tool' While insulin resistance has been linked to AD onset and pathology, its role in how rapidly the condition progresses has remained unclear. The single-center retrospective study included 315 patients without diabetes who had a neurodegenerative disorder (NDD) detected through cerebrospinal fluid (CSF). Of these, 210 had AD (mean age, 71.51 years; 79% men), and 115 had another NDD, mostly Lewy body dementia or frontotemporal dementia (mean age, 69.19; 60% men). Baseline measurements included neurologic evaluations, the Mini-Mental State Examination (MMSE) to test cognition, CSF biomarkers (Abeta42 or pTau181), APOE4 genotyping, and blood-brain barrier (BBB) integrity (CSF/serum albumin ratio). Follow-up assessments involved cognitive testing, typically every 6 months, with most patients followed for 3 years. Cognitive decline was defined as a loss of more than 2.5 points per year on the MMSE. Investigators measured insulin resistance with the TyG index, a metabolic marker calculated from fasting triglycerides and fasting glucose levels. The index, which Gumina called a 'practical tool,' can be obtained from standard blood tests. Researchers stratified patients into tertiles (low, medium, or high) according to TyG index levels. Exacerbating Neuroinflammation After adjusting for age, sex, baseline MMSE, disease duration, AD therapy, and BMI, the study found high TyG was significantly associated with faster cognitive decline over 3 years in a subgroup of 161 subjects with MCI (77% men) compared to those with lower TyG levels (hazard ratio, 4.08; 95% CI, 1.06-15.73). Insulin resistance may accelerate AD progression by impairing brain glucose uptake, said Gumina. This could exacerbate neuroinflammation and disrupt the BBB, 'all of which accelerate neurodegeneration,' she added. The study did link high TyG to elevated BBB permeability, but only in patients with AD. 'This supports the hypothesis that metabolic dysfunction may worsen neurodegeneration via mechanisms specifically related to AD,' said Gumina. Researchers observed an association between TyG and conversion from MCI to dementia, although this trend was not significant. Insulin resistance did not affect clinical progression in those with a neurodegenerative disease other than AD, which again likely reflects a disease-specific mechanism, said Gumina. 'AD may be the most sensitive to metabolic stress due to its underlying pathology,' she said. The study found no significant interaction between TyG and APOE4 genotype on the rate of cognitive decline. Speeding Disease Progression These new results show that insulin resistance 'influences the speed of disease progression, especially in early stages, which could be the most vulnerable in modifying the trajectory,' said Gumina. The findings could lead to more prompt identification of high-risk patients. 'By using the TyG index, we can stratify MCI patients by risk of fast progression, enabling personalized follow-up and interventions when the brain is still more responsive,' said Gumina. She recommends more widespread use of the TyG test, especially in patients with MCI or early AD. 'It's already available through routine and simple blood tests, found in every lab, so it could be used to flag patients for closer monitoring or early intervention.' Such interventions could include targeted enrollment in anti-amyloid or anti-tau clinical trials and timely introduction of lifestyle modifications and perhaps medications to improve insulin sensitivity. 'Lifestyle changes like regular exercise, a healthy diet, weight control, and managing blood pressure and cholesterol are all effective,' said Gumina. 'Some medications that modify insulin resistance are also under investigation.' The research team is investigating whether the TyG index correlates with neuroimaging biomarkers and integrating it with genetic and imaging data to improve prediction models. Important Puzzle Piece Commenting on the findings for Medscape Medical News , Sebastiaan Engelborghs, MD, PhD, professor and chair of Neurology, Vrije University Brussels, Brussels, Belgium, said the study 'adds an important piece to the Alzheimer's puzzle . ' The results highlighted how a routine metabolic marker such as the TyG index could help identify patients most likely to benefit from early, targeted interventions, said Engelborghs, who co-chaired the EAN panel on dementia and was not part of the research. And with precision neurology becoming ever more relevant, 'such noninvasive and low-cost tools could become critical in tailoring care and optimizing clinical trial design,' he added. Engelborghs agreed lifestyle interventions could affect insulin resistance and noted research shows that 45% of dementias can be prevented or delayed by modifying 14 risk factors. One such risk factor is obesity, and insulin resistance 'goes hand and hand' with obesity, he said. 'We expect that people who modify their lifestyle in order to lose weight and reduce insulin resistance will decline more slowly,' Engelborghs said.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store